Drospirenone is under clinical development by Insud Pharma and currently in Phase III for Endometriosis. According to GlobalData, Phase III drugs for Endometriosis have a 17% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Drospirenone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Drospirenone overview
Drospirenone (Slynd, Slinda, Lyzbet) is a synthetic spironolactone analogue with anti-mineralocorticoid activity. It is formulated as film coated tablets, chewable tablets and coated tablets for oral route of administration. Drospirenone is indicated for use by females of reproductive potential to prevent pregnancy.
Drospirenone is under development as the hormonal contraceptive in female patients, endometriosis. It is administered orally as a Film-coated tablet. The drug candidate is a synthetic progestogen which acts by targeting the progesterone receptor.
Insud Pharma overview
Insud Pharma(Insud) formerly known as Chemo Espana, is a pharmaceutical company, which conducts research, development, manufacture, sales and marketing of active pharmaceutical ingredients (APIs), finished dosage forms and branded pharmaceuticals. Its product portfolio includes steroids, hormones and antibiotics in different formulations such as tablets, capsules, injectables and suspensions. The company’s target therapy areas include cardiovascular, gastroenterology, anti-infective, central nervous system, respiratory, women’s healthcare, endocrinology, dermatology and urology. Insud’s OTC division develops food supplements in the form of soft gel capsules, hard capsules, tablets, pellets, sachets to cosmetics covering metabolic syndrome, digestive disorders, women and men healthcare, weigh control or quality of life. It has presence in Europe, South America, Asia and North America. Insud is headquartered in Madrid, Spain.
For a complete picture of Drospirenone’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
